Monte Rosa Signs License Agreement with Novartis to Develop VAV1 MGDs

BASEL (dpa-AFX) – Biotechnology company Monte Rosa Therapeutics, Inc. (GLUE) announced a global exclusive development and commercialization licensing agreement with Novartis AG (NVS) to develop Molecular Glue Disintegrators, or MGDs, for T- and B-cell-modulated VAV1. Including MRT-6160.

MRT-6160 is currently in an ongoing Phase 1, single ascending dose (SAD)/multiple ascending dose (MAD) healthy volunteer study for immune-mediated conditions.

Under the terms of the agreement, Novartis will have exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 clinical studies.

Monte Rosa remains responsible for completing the ongoing Phase 1 clinical study of MRT-6160.

Novartis agreed to pay $150 million upfront to Monte Rosa. Monte Rosa is entitled to receive up to $2.1 billion in development, regulatory and sales phases, starting with the start of Phase 2, as well as tiered royalties on ex-U.S. net sales.

Monte Rosa will co-finance Phase 3 clinical developments and share any profits and losses related to the manufacturing and commercialization of MRT-6160 in the US

The deal is subject to customary closing conditions, including regulatory approvals.

Related Posts